Viridian Therapeutics announced trial results of its intravenously delivered treatment for chronic thyroid eye disease (TED), showing patients experienced reductions in proptosis and improvements in their clinical activity scores.
The double-masked, placebo-controlled phase 1/2 trial of VRDN-001, an investigational full antagonist antibody to the insulin-like growth factor 1 receptor, involved 12 patients who were given two doses three weeks apart. VRDN-001 was generally well tolerated among all treated patients, who will continue to be evaluated for safety and durability of response, said trial investigator Dr Kimberly Cockerham, an oculoplastic surgeon at the Senta Clinic in San Diego, California. “Thus far, these data suggest that VRDN-001 has the potential to become an important new treatment option for managing the signs and symptoms of TED.”
In related news, Viridian’s Thrive phase 3 trial will now be amended to include a five-dose treatment regimen of VRDN-001 and placebo arms only. Viridian said the amendment acknowledges key stakeholder feedback from the TED community who expressed a preference for a shorter treatment regimen. The company said it will announce topline results in mid-2024 and plans to begin the Thrive phase 3 trial in patients with chronic TED in the third quarter of 2023.
